ABBOTT LABORATORIES Aktie

 

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet....

NVST vs. ABT: Which Stock Is the Better Value Option?...

Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

Abbott Laboratories (NYSE:ABT) currently trades at $105.70, while the Street's consensus price target sits at $118.42, implying roughly 12% of upside. Barclays analyst Matt Miksic carries the highest active target at $143, translating to about 35% in gains from here. Abbott is a diversified healthcare giant with a market cap near $182.9 billion, operating across ... Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant...

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors....

Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement....

Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch....

ABT's earnings beat and higher profit outlook strengthen its case, but can growth in devices and diagnostics overcome valuation and acquisition concerns?...

GM, ABT and JNJ stand out this earnings season after raising guidance, boosting outlooks and reinforcing momentum with stronger-than-expected quarterly results....

SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating a data breachthat led to unauthorized access to the sensitive information of patients affiliated with Abbott Laboratories ("Abbott"), an Illinois-based healthcare and medical device company, and......

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth....

JNJ is pruning its portfolio while Abbott just dropped $21 billion to expand into cancer diagnostics, and the two strategies are pulling their stocks in completely opposite directions. Which move looks smarter when you dig into the actual earnings?...

TEMPE, Ariz.--(BUSINESS WIRE)--21st Century Healthcare, Inc. ("21st Century" or the "Company"), a leading manufacturer of vitamins, minerals, and supplements, and a portfolio company of Grant Avenue Capital LLC ("Grant Avenue"), a healthcare-focused, middle-market private equity firm, today announced the appointment of Katie Doyle to its Board of Directors. Ms. Doyle brings over 30 years of experience leading and advising consumer health and wellness companies. She most recently served as Executive Chair of FoodScience Corporation, a manufacturer of nutritional supplements with branded, private label, and co-manufacturing lines of business. Prior to FoodScience, Ms. Doyle was Chief Executive Officer of Swanson Health, a private equity-backed e-commerce health and wellness business, and Senior Vice President and Corporate Officer at Abbott Laboratories, where she led the Abbott Nutrition Products Division responsible for a $3.2 billion portfolio of consumer health brands. Ms. ...

Abbott's raised 2026 earnings outlook and four growth drivers point to a faster second half across nutrition, devices, diagnostics and diabetes care....

NORTH CHICAGO (dpa-AFX) - Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid or......

Today's top gainers in the biotech space include CareDx, which rallied after Medicare finalized its Local Coverage Determination process for molecular testing of solid organ allograft rejection; AtaiBeckley, after agreeing to be acquired by Eli Lilly; and Abbott, after reporting second-quarter results and providing an upbeat outlook, among others....

Monatelang wollten Investoren von Abbott Laboratories nichts wissen, die Aktie fiel auf ein neues Mehrjahrestief. Jetzt meldet sie sich eindrucksvoll zurück....